Qurient Co., Ltd.

ACTIVE

8/F PDCC Tower C Bldg., 京畿道城南市, 京畿道, South Koreawww.qurient.comPublic32 employeesEstablished: 2008-07-02

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2008

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

60.0%

Phase 2

40.0%

Trial Status Distribution

Active, not recruiting

10.0%

Completed

60.0%

Recruiting

20.0%

Terminated

10.0%

Clinical Trials

Trials sponsored by this organization (10)

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

Phase 1

Recruiting

interventional

Dec 202518 participants

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Phase 1

Active, not recruiting

interventional

Jan 2023120 participants

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Phase 1

Recruiting

interventional

Aug 2022130 participants

A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients

Phase 2

Terminated

interventional

Jul 20211 participant

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor

Phase 1

Completed

interventional

Nov 202051 participants

A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

Phase 2

Completed

interventional

Jul 201860 participants

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

Phase 2

Completed

interventional

Jun 2018258 participants

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

Phase 1

Completed

interventional

Aug 201647 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations